Episode 064: Breast Cancer Series, Pt. 9-Triple Negative, Early Stage Breast Cancer The Fellow on Call: The Heme/Onc Podcast
-
- Medicine
This week, we round out our discussion on the early stage breast cancer, turning our attention to the triple negative subtype. Once again, there are a lot of trials and data, but be sure to check out the show notes for the highlights!
Content:
- What is TNBC?
-What is the data to support the use of neoadjuvant therapy in this disease?
- What is "pathologic CR" and how is different than "residual cancer burden"?
- Can we ever omit neoadjuvant therapy?
- What are our options for chemotherapy regimens in neoadjuvant and adjuvant setting?
** This episode has been sponsored by HemOnc.org
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we round out our discussion on the early stage breast cancer, turning our attention to the triple negative subtype. Once again, there are a lot of trials and data, but be sure to check out the show notes for the highlights!
Content:
- What is TNBC?
-What is the data to support the use of neoadjuvant therapy in this disease?
- What is "pathologic CR" and how is different than "residual cancer burden"?
- Can we ever omit neoadjuvant therapy?
- What are our options for chemotherapy regimens in neoadjuvant and adjuvant setting?
** This episode has been sponsored by HemOnc.org
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast